Startups

Manager, Clinical Supply Chain

Rapport Therapeutics · 99 High Street, Suite 2100 , Boston, MA 02110 · On-site

← All jobs
About Rapport Therapeutics

Precision medicines to match the complexity of the human brain. Backed by Third Rock Ventures.

About the role

Rapport Therapeutics is seeking a detail-oriented and execution-focused Manager, Clinical Supply Chain to support global supply chain operations for late-stage clinical development and commercialization readiness. As the company advances its lead programs through Phase 3 and prepares for potential regulatory submissions, this role will support the execution of reliable, compliant, and scalable supply across global clinical trials. Found on 1752vc Careers, the job board for startup and VC roles.

What they're looking for

  • 3–5 years of progressive experience in global supply chain or clinical supply chain management within the biopharmaceutical industry
  • Bachelor's degree in Life Sciences, Engineering, Supply Chain, or related field
  • Experience supporting Phase 2/3 clinical trials
  • Experience supporting commercial supply chain activities is a plus
  • Understanding of clinical development processes, GMP/GDP requirements, and global regulatory expectations for small molecule therapeutics
  • Experience supporting external manufacturing, packaging, labeling, and logistics partners
More about this role

When our people share why they joined Rapport and love it here, it comes down to three things: the science, the mission, and the team. At Rapport, we’re driven by a passion for developing precision neuromedicines with the potential for fewer side effects, enabling patients and their families to enjoy healthier, more fulfilling lives. And we’re doing this with extraordinary science and awesome people (affectionately called Rapptors).

Our innovative scientific platform is centered on Receptor Associate Proteins (RAPs). RAPs are a component of neuronal receptor complexes, which play a crucial role in regulating receptor assembly and function. This precision approach has the potential to revolutionize the development of small molecule therapies. We are excited about the potential of our lead program, RAP-219. Our first indication targets focal epilepsy with additional clinical trials in primary generalized tonic-clonic seizures (PGTCS) and bipolar disorder.

The strength of Rapport comes from our Rapptors – who are united by our mission to improve patients lives. We bring the heart and hustle to advance our science forward, always staying true to our core values. We hope you’re as...

Read the full posting on Rapport Therapeutics's site ↗

Supply Chain

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.